| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-02-19 |
| タイトル |
|
|
タイトル |
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Akagi, Kazumasa
Taniguchi, Hirokazu
Fukuda, Minoru
Yamazaki, Takuya
Takao, Daisuke
Tagawa, Ryuta
Hayashi, Fumiko
Ogata, Ryosuke
Ono, Sawana
Tomono, Hiromi
Suyama, Takayuki
Honda, Noritaka
Umeyama, Yasuhiro
Dotsu, Yosuke
Matsuo, Midori
Gyotoku, Hiroshi
Senju, Hiroaki
Takemoto, Shinnosuke
Soda, Hiroshi
Mizowaki, Takashi
Ikeda, Takaya
Nagashima, Seiji
Tasaki, Yutaro
Nakamura, Daisuke
Komiya, Kazutoshi
Nakatomi, Katsumi
Sasaki, Eisuke
Hirakawa, Koichi
Toya, Ryo
Ashizawa, Kazuto
Mukae, Hiroshi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Etoposide plus cisplatin (EP) with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) remains the standard treatment for unresectable limited-stage (LS) small cell lung cancer (SCLC)) for over two decades. Our previous study demonstrated that amrubicin plus cisplatin (AP) with once-daily thoracic radiotherapy (50 Gy per 25 fractions) for LS-SCLC prolonged overall survival (OS) to 39.5 months with manageable toxicities. To enhance therapeutic efficacy, this study aimed to assess the feasibility of AP combined with AHTRT for LS-SCLC. Methods: Treatment-naïve patients aged 20–75 years with LS-SCLC, performance status 0–1, and adequate organ function were enrolled. Chemotherapy consisted of cisplatin 60 mg/m2/day (day 1) and amrubicin (days 1–3), administered concurrently with AHTRT (1.5 Gy/time, twice daily, 45 Gy in total). The initial amrubicin dose was set to 25 mg/m2 and increased to 35 mg/m2 from the second cycle. Results: Nine patients were enrolled in this study. Dose-limiting toxicities included Grade 3 febrile neutropenia and Grade 3 hypokalemia. The recommended and maximum tolerated dose of amrubicin was 25 mg/m2. The overall response rate was 100%, with both median progression-free survival and OS not reached. The 5-year OS rate was 64.8%. Conclusion: AP combined with AHTRT from the first chemotherapy cycle was well tolerated at the recommended amrubicin dose of 25 mg/m2. This regimen demonstrated promising efficacy and may represent a potential therapeutic option for LS-SCLC. |
|
言語 |
en |
| 書誌情報 |
en : Lung Cancer
巻 214,
p. art. no. 109310,
発行日 2026-02-10
|
| 出版者 |
|
|
出版者 |
Elsevier B.V. |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
01695002 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.lungcan.2026.109310 |
| 権利 |
|
|
権利情報 |
© 2026 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Lung Cancer, 214, art. no. 109310; 2026 |
|
言語 |
en |
LC214_109310.pdf (503 KB)
